Clinical Trial Update: Pharmacokinetics of Rivaroxaban After Bariatric Surgery [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of rivaroxaban in patients after bariatric surgery to assess how the procedure affects drug exposure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morbid Obesity

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: University Hospital, Brest | Conditions: Bariatric Surgery, Morbid Obesity | Phase 1 | Status: COMPLETED